Emerging treatments for amyloidosis | Zendy

Rabya Sayed | Zendy; Philip N. Hawkins | Zendy; Helen J. Lachmann | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Emerging treatments for amyloidosis

Author(s) -

Rabya Sayed,

Philip N. Hawkins,

Helen J. Lachmann

Publication year - 2014

Publication title -

kidney international

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.499

H-Index - 276

eISSN - 1523-1755

pISSN - 0085-2538

DOI - 10.1038/ki.2014.368

Subject(s) - amyloidosis , medicine , fibrillogenesis , al amyloidosis , amyloid fibril , amyloid (mycology) , clinical trial , immunology , disease , pathology , immunoglobulin light chain , antibody , chemistry , fibril , amyloid β , biochemistry

Amyloidosis results from protein misfolding, and ongoing amyloid deposition can ultimately lead to organ failure and death. Historically, this is a group of diseases with limited treatment options and frequently poor prognosis. However, there are now 'targeted' therapeutics emerging in the form of stabilizers of the precursor protein, inhibitors of fibrillogenesis, fibril disruptors, and blockers of protein translation, transcription, and immunotherapy. We review many of these approaches that are currently being assessed in clinical trials.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research